Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 820813, 11 pages
http://dx.doi.org/10.1155/2015/820813
Review Article

Immunotherapy for Bone and Soft Tissue Sarcomas

1Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan
2Department of Immunology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan
3Center of Innovative Medicine, Okayama University Hospital, Okayama 700-8558, Japan
4Department of Intelligent Orthopaedic System, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan
5Department of Medical Materials for Musculoskeletal Reconstruction, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan

Received 25 July 2014; Accepted 13 November 2014

Academic Editor: Mohammad Owais

Copyright © 2015 Takenori Uehara et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Z. Burningham, M. Hashibe, L. Spector et al., “The epidemiology of sarcoma,” Clinical Sarcoma Research, vol. 2, no. 1, p. 14, 2012. View at Publisher · View at Google Scholar
  2. National Cancer Institute, A Snapshot of Sarcoma, 2013.
  3. T. A. Damron, W. G. Ward, and A. Stewart, “Osteosarcoma, chondrosarcoma, and Ewing's sarcoma: national cancer data base report,” Clinical Orthopaedics and Related Research, no. 459, pp. 40–47, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. L. A. Doyle, “Sarcoma classification: an update based on the 2013 world health organization classification of tumors of soft tissue and bone,” Cancer, vol. 120, no. 12, pp. 1763–1774, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Italiano, A. le Cesne, J. Mendiboure et al., “Prognostic factors and impact of adjuvant treatments on local and metastatic relapse of soft-tissue sarcoma patients in the competing risks setting,” Cancer, vol. 120, no. 21, pp. 3361–3369, 2014. View at Google Scholar
  6. M. A. Tucker, G. J. D'Angio, J. D. Boice Jr. et al., “Bone sarcomas linked to radiotherapy and chemotherapy in children,” The New England Journal of Medicine, vol. 317, no. 10, pp. 588–593, 1987. View at Publisher · View at Google Scholar · View at Scopus
  7. A. N. van Geel, U. Pastorino, K. W. Jauch et al., “Surgical treatment of lung metastases: the European organization for research and treatment of cancer-soft tissue and bone sarcoma group study of 255 patients,” Cancer, vol. 77, no. 4, pp. 675–682, 1996. View at Publisher · View at Google Scholar
  8. S. S. Bielack, B. Kempf-Bielack, G. Delling et al., “Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols,” Journal of Clinical Oncology, vol. 20, no. 3, pp. 776–790, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. L. Mulder Renée, M. Paulides, T. Langer, L. C. Kremer, and E. C. van Dalen, “Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients,” Cochrane Database of Systematic Reviews, vol. 17, no. 2, Article ID CD006300, 2012. View at Publisher · View at Google Scholar
  10. W. B. Coley, “II. Contribution to the knowledge of sarcoma,” Annals of Surgery, vol. 14, no. 3, pp. 199–220, 1891. View at Google Scholar
  11. J. Kluwe, A. Mencin, and R. F. Schwabe, “Toll-like receptors, wound healing, and carcinogenesis,” Journal of Molecular Medicine, vol. 87, no. 2, pp. 125–138, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. F. Balkwill, “Tumour necrosis factor and cancer,” Nature Reviews Cancer, vol. 9, no. 5, pp. 361–371, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. R. L. Modlin, “Innate immunity: ignored for decades, but not forgotten,” Journal of Investigative Dermatology, vol. 132, no. 3, pp. 882–886, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. J. F. M. Jacobs, F. Brasseur, C. A. Hulsbergen-van de Kaa et al., “Cancer-germline gene expression in pediatric solid tumors using quantitative real-time PCR,” International Journal of Cancer, vol. 120, no. 1, pp. 67–74, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. K. M. Skubitz, S. Pambuccian, J. C. Carlos, and A. P. N. Skubitz, “Identification of heterogeneity among soft tissue sarcomas by gene expression profiles from different tumors,” Journal of Translational Medicine, vol. 6, article 23, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. W. Schwinger, V. Klass, M. Benesch et al., “Feasibility of high-dose interleukin-2 in heavily pretreated pediatric cancer patients,” Annals of Oncology, vol. 16, no. 7, pp. 1199–1206, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Ito, K. Murakami, T. Yanagawa et al., “Effect of human leukocyte interferon on the metastatic lung tumor of osteosarcoma: case reports,” Cancer, vol. 46, no. 7, pp. 1562–1565, 1980. View at Google Scholar
  18. J. H. Edmonson, H. J. Long, S. Frytak, W. A. Smithson, and L. M. Itri, “Phase II study of recombinant alfa-2a interferon in patients with advanced bone sarcomas,” Cancer Treatment Reports, vol. 71, no. 7-8, pp. 747–748, 1987. View at Google Scholar · View at Scopus
  19. C. R. Müller, S. Smeland, H. C. F. Bauer, G. Sæter, and H. Strander, “Interferon-α as the only adjuvant treatment in high-grade osteosarcoma: long term results of the Karolinska Hospital series,” Acta Oncologica, vol. 44, no. 5, pp. 475–480, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. K. Winkler, G. Beron, R. Kotz et al., “Neoadjuvant chemotherapy for osteogenic sarcoma: Results of a cooperative German/Austrian study,” Journal of Clinical Oncology, vol. 2, no. 6, pp. 617–624, 1984. View at Google Scholar · View at Scopus
  21. S. S. Bielack, S. Smeland, J. Whelan et al., “MAP plus maintenance pegylated interferon alpha-2b (MAPIfn) versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: first results of the EURAMOS-1 “good response” randomization,” Journal of Clinical Oncology, vol. 31, no. 18, 2013. View at Google Scholar
  22. L. Kager, U. Potschger, and S. Bielack, “Review of mifamurtide in the treatment of patients with osteosarcoma,” Therapeutics and Clinical Risk Management, vol. 6, no. 279–286, 2010. View at Google Scholar
  23. R. Dillman, N. Barth, S. Selvan et al., “Phase I/II trial of autologous tumor cell line-derived vaccines for recurrent or metastatic sarcomas,” Cancer Biotherapy and Radiopharmaceuticals, vol. 19, no. 5, pp. 581–588, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. C. L. Mackall, E. H. Rhee, E. J. Read et al., “A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas,” Clinical Cancer Research, vol. 14, no. 15, pp. 4850–4858, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Suminoe, A. Matsuzaki, H. Hattori, Y. Koga, and T. Hara, “Immunotherapy with autologous dendritic cells and tumor antigens for children with refractory malignant solid tumors,” Pediatric Transplantation, vol. 13, no. 6, pp. 746–753, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Kawaguchi, T. Tsukahara, K. Ida et al., “SYT-SSX breakpoint peptide vaccines in patients with synovial sarcoma: a study from the Japanese Musculoskeletal Oncology Group,” Cancer Science, vol. 103, no. 9, pp. 1625–1630, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. R. G. Maki, A. A. Jungbluth, S. Gnjatic et al., “A pilot study of anti-CTLA4 antibody ipilimumab in patients with synovial sarcoma,” Sarcoma, vol. 2013, Article ID 168145, 8 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. P. F. Robbins, R. A. Morgan, S. A. Feldman et al., “Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1,” Journal of Clinical Oncology, vol. 29, no. 7, pp. 917–924, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. G. Schuler, B. Schuler-Thurner, and R. M. Steinman, “The use of dendritic cells in cancer immunotherapy,” Current Opinion in Immunology, vol. 15, no. 2, pp. 138–147, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. L. Gattinoni, D. J. Powell Jr., S. A. Rosenberg, and N. P. Restifo, “Adoptive immunotherapy for cancer: building on success,” Nature Reviews Immunology, vol. 6, no. 5, pp. 383–393, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. S. A. Rosenberg, N. P. Restifo, J. C. Yang, R. A. Morgan, and M. E. Dudley, “Adoptive cell transfer: a clinical path to effective cancer immunotherapy,” Nature Reviews Cancer, vol. 8, no. 4, pp. 299–308, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. S. A. Rosenberg, J. J. Mule, P. J. Spiess, C. M. Reichert, and S. L. Schwarz, “Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2,” The Journal of Experimental Medicine, vol. 161, no. 5, pp. 1169–1188, 1985. View at Publisher · View at Google Scholar · View at Scopus
  33. W. H. West, K. W. Tauer, J. R. Yannelli et al., “Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer,” The New England Journal of Medicine, vol. 316, no. 15, pp. 898–905, 1987. View at Publisher · View at Google Scholar · View at Scopus
  34. S. A. Rosenberg, P. Spiess, and R. Lafreniere, “A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes,” Science, vol. 233, no. 4770, pp. 1318–1321, 1986. View at Publisher · View at Google Scholar · View at Scopus
  35. S. A. Rosenberg, J. C. Yang, and N. P. Restifo, “Cancer immunotherapy: moving beyond current vaccines,” Nature Medicine, vol. 10, no. 9, pp. 909–915, 2004. View at Publisher · View at Google Scholar · View at Scopus
  36. K. E. de Visser, A. Eichten, and L. M. Coussens, “Paradoxical roles of the immune system during cancer development,” Nature Reviews Cancer, vol. 6, no. 1, pp. 24–37, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. R. Medzhitov and C. A. Janeway Jr., “Innate immunity: the virtues of a nonclonal system of recognition,” Cell, vol. 91, no. 3, pp. 295–298, 1997. View at Publisher · View at Google Scholar · View at Scopus
  38. C. A. Janeway Jr. and R. Medzhitov, “Innate immune recognition,” Annual Review of Immunology, vol. 20, no. 1, pp. 197–216, 2002. View at Publisher · View at Google Scholar · View at Scopus
  39. T. Kawai and S. Akira, “TLR signaling,” Cell Death & Differentiation, vol. 13, no. 5, pp. 816–825, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. K. Takeda and S. Akira, “TLR signaling pathways,” Seminars in Immunology, vol. 16, no. 1, pp. 3–9, 2004. View at Publisher · View at Google Scholar · View at Scopus
  41. H. R. MacDonald and M. Nabholz, “T-cell activation,” Annual Review of Cell Biology, vol. 2, pp. 231–253, 1986. View at Publisher · View at Google Scholar · View at Scopus
  42. J. E. Smith-Garvin, G. A. Koretzky, and M. S. Jordan, “T cell activation,” Annual Review of Immunology, vol. 27, pp. 591–619, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. A. Grakoui, S. K. Bromley, C. Sumen et al., “The immunological synapse: a molecular machine controlling T cell activation,” Science, vol. 285, no. 5425, pp. 221–227, 1999. View at Publisher · View at Google Scholar · View at Scopus
  44. S. M. Kaech, E. J. Wherry, and R. Ahmed, “Effector and memory T-cell differentiation: implications for vaccine development,” Nature Reviews Immunology, vol. 2, no. 4, pp. 251–262, 2002. View at Publisher · View at Google Scholar · View at Scopus
  45. S. M. Kaech, S. Hemby, E. Kersh, and R. Ahmed, “Molecular and functional profiling of memory CD8 T cell differentiation,” Cell, vol. 111, no. 6, pp. 837–851, 2002. View at Publisher · View at Google Scholar · View at Scopus
  46. D. Mauri, T. Wyss-Coray, H. Gallati, and W. J. Pichler, “Antigen-presenting T cells induce the development of cytotoxic CD4+ T cells. I. Involvement of the CD80-CD28 adhesion molecules,” The Journal of Immunology, vol. 155, no. 1, pp. 118–127, 1995. View at Google Scholar · View at Scopus
  47. I. S. Grewal and R. A. Flavell, “A central role of CD40 ligand in the regulation of CD4+ T-cell responses,” Immunology Today, vol. 17, no. 9, pp. 410–414, 1996. View at Publisher · View at Google Scholar · View at Scopus
  48. S. R. M. Bennett, F. R. Carbone, F. Karamalis, R. A. Flaveli, J. F. A. P. Miller, and W. R. Heath, “Help for cytotoxic-T-cell responses is mediated by CD40 signalling,” Nature, vol. 393, no. 6684, pp. 478–480, 1998. View at Publisher · View at Google Scholar · View at Scopus
  49. K. Murali-Krishna, J. D. Altman, M. Suresh et al., “Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection,” Immunity, vol. 8, no. 2, pp. 177–187, 1998. View at Publisher · View at Google Scholar · View at Scopus
  50. R. M. Steinman, “The dendritic cell system and its role in immunogenicity,” Annual Review of Immunology, vol. 9, pp. 271–296, 1991. View at Publisher · View at Google Scholar · View at Scopus
  51. J. Banchereau and R. M. Steinman, “Dendritic cells and the control of immunity,” Nature, vol. 392, no. 6673, pp. 245–252, 1998. View at Publisher · View at Google Scholar · View at Scopus
  52. M. L. Albert, B. Sauter, and N. Bhardwaj, “Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLS,” Nature, vol. 392, no. 6671, pp. 86–89, 1998. View at Publisher · View at Google Scholar · View at Scopus
  53. M. Corr, A. E. Slanetz, L. F. Boyd et al., “T cell receptor-MHC class I peptide interactions: affinity, kinetics, and specificity,” Science, vol. 265, no. 5174, pp. 946–949, 1994. View at Publisher · View at Google Scholar · View at Scopus
  54. P. R. Scholl, P. R. Scholl, R. S. Geha, and R. S. Geha, “MHC class II signaling in B-cell activation,” Immunology Today, vol. 15, no. 9, pp. 418–422, 1994. View at Publisher · View at Google Scholar · View at Scopus
  55. W. R. Heath and F. R. Carbone, “Cross-presentation, dendritic cells, tolerance and immunity,” Annual Review of Immunology, vol. 19, no. 1, pp. 47–64, 2001. View at Publisher · View at Google Scholar · View at Scopus
  56. H. Udono, T. Yamano, Y. Kawabata, M. Ueda, and K. Yui, “Generation of cytotoxic T lymphocytes by MHC class I ligands fused to heat shock cognate protein 70,” International Immunology, vol. 13, no. 10, pp. 1233–1242, 2001. View at Publisher · View at Google Scholar · View at Scopus
  57. A. L. Ackerman and P. Cresswell, “Cellular mechanisms governing cross-presentation of exogenous antigens,” Nature Immunology, vol. 5, no. 7, pp. 678–684, 2004. View at Publisher · View at Google Scholar · View at Scopus
  58. M. Chiriva-Internati, A. Pandey, R. Saba et al., “Cancer testis antigens: a novel target in lung cancer,” International Reviews of Immunology, vol. 31, no. 5, pp. 321–343, 2012. View at Publisher · View at Google Scholar · View at Scopus
  59. E. Stockert, E. Jäger, Y.-T. Chen et al., “A survey of the humoral immune response of cancer patients to a panel of human tumor antigens,” Journal of Experimental Medicine, vol. 187, no. 8, pp. 1349–1354, 1998. View at Publisher · View at Google Scholar · View at Scopus
  60. C. Coppin, F. Porzsolt, J. Kumpf, A. Coldman, and T. Wilt, “Immunotherapy for advanced renal cell cancer,” Cochrane Database of Systematic Reviews, 2004. View at Google Scholar · View at Scopus
  61. A. D. Sasse, E. C. Sasse, L. G. O. Clark, L. Ulloa, and O. A. C. Clark, “Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma,” Cochrane Database of Systematic Reviews, Article ID CD005413, 2007. View at Publisher · View at Google Scholar · View at Scopus
  62. G. A. Rabinovich, D. Gabrilovich, and E. M. Sotomayor, “Immunosuppressive strategies that are mediated by tumor cells,” Annual Review of Immunology, vol. 25, pp. 267–296, 2007. View at Publisher · View at Google Scholar · View at Scopus
  63. T. L. Walunas, D. J. Lenschow, C. Y. Bakker et al., “CTLA-4 can function as a negative regulator of T cell activation,” Immunity, vol. 1, no. 5, pp. 405–413, 1994. View at Publisher · View at Google Scholar · View at Scopus
  64. P. S. Linsley, J. L. Greene, W. Brady et al., “Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors,” Immunity, vol. 1, no. 9, pp. 793–801, 1994. View at Google Scholar
  65. K. Wing, Y. Onishi, P. Prieto-Martin et al., “CTLA-4 control over Foxp3+ regulatory T cell function,” Science, vol. 322, no. 5899, pp. 271–275, 2008. View at Publisher · View at Google Scholar · View at Scopus
  66. E. R. Kearney, T. L. Walunas, R. W. Karr et al., “Antigen-dependent clonal expansion of a trace population of antigen-specific CD4+ T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4,” The Journal of Immunology, vol. 155, no. 3, pp. 1032–1036, 1995. View at Google Scholar · View at Scopus
  67. D. L. Barber, E. J. Wherry, D. Masopust et al., “Restoring function in exhausted CD8 T cells during chronic viral infection,” Nature, vol. 439, no. 7077, pp. 682–687, 2006. View at Publisher · View at Google Scholar · View at Scopus
  68. C. Petrovas, J. P. Casazza, J. M. Brenchley et al., “PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection,” The Journal of Experimental Medicine, vol. 203, no. 10, pp. 2281–2292, 2006. View at Publisher · View at Google Scholar · View at Scopus
  69. K. Sakuishi, L. Apetoh, J. M. Sullivan, B. R. Blazar, V. K. Kuchroo, and A. C. Anderson, “Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity,” Journal of Experimental Medicine, vol. 207, no. 10, pp. 2187–2194, 2010. View at Publisher · View at Google Scholar · View at Scopus
  70. Y. Latchman, C. R. Wood, T. Chernova et al., “PD-L2 is a second ligand for PD-1 and inhibits T cell activation,” Nature Immunology, vol. 2, no. 3, pp. 261–268, 2001. View at Publisher · View at Google Scholar · View at Scopus
  71. M. K. Callahan and J. D. Wolchok, “At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy,” Journal of Leukocyte Biology, vol. 94, no. 1, pp. 41–53, 2013. View at Publisher · View at Google Scholar · View at Scopus
  72. D. M. Pardoll, “The blockade of immune checkpoints in cancer immunotherapy,” Nature Reviews Cancer, vol. 12, no. 4, pp. 252–264, 2012. View at Publisher · View at Google Scholar · View at Scopus
  73. A. Chaudhry, D. Rudra, P. Treuting et al., “CD4+ regulatory T cells control TH17 responses in a stat3-dependent manner,” Science, vol. 326, no. 5955, pp. 986–991, 2009. View at Publisher · View at Google Scholar · View at Scopus
  74. J. R. Brahmer, S. S. Tykodi, L. Q. M. Chow et al., “Safety and activity of anti-PD-L1 antibody in patients with advanced cancer,” The New England Journal of Medicine, vol. 366, no. 26, pp. 2455–2465, 2012. View at Publisher · View at Google Scholar · View at Scopus
  75. Y. Iwai, M. Ishida, Y. Tanaka, T. Okazaki, T. Honjo, and N. Minato, “Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 19, pp. 12293–12297, 2002. View at Publisher · View at Google Scholar · View at Scopus
  76. L. M. Francisco, V. H. Salinas, K. E. Brown et al., “PD-L1 regulates the development, maintenance, and function of induced regulatory T cells,” Journal of Experimental Medicine, vol. 206, no. 13, pp. 3015–3029, 2009. View at Publisher · View at Google Scholar · View at Scopus
  77. S. Lee and K. Margolin, “Cytokines in cancer immunotherapy,” Cancers, vol. 3, no. 4, pp. 3856–3893, 2011. View at Publisher · View at Google Scholar · View at Scopus
  78. J.-P. Shaw, P. J. Utz, D. B. Durand, J. J. Toole, E. A. Emmel, and G. R. Crabtree, “Indentification of a putative regulator of early T cell activation genes,” Science, vol. 241, no. 4862, pp. 202–205, 1988. View at Publisher · View at Google Scholar · View at Scopus
  79. M. T. Lotze, A. E. Chang, C. A. Seipp, C. Simpson, J. T. Vetto, and S. A. Rosenberg, “High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings,” The Journal of the American Medical Association, vol. 256, no. 22, pp. 3117–3124, 1986. View at Publisher · View at Google Scholar · View at Scopus
  80. M. B. Atkins, M. T. Lotze, J. P. Dutcher et al., “High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993,” Journal of Clinical Oncology, vol. 17, no. 7, pp. 2105–2116, 1999. View at Google Scholar · View at Scopus
  81. R. N. Schwartz, L. Stover, and J. Dutcher, “Managing toxicities of high-dose interleukin-2,” Oncology, vol. 16, no. 11, pp. 11–20, 2002. View at Google Scholar · View at Scopus
  82. D. J. Schwartzentruber, “Guidelines for the safe administration of high-dose interleukin-2,” Journal of Immunotherapy, vol. 24, no. 4, pp. 287–293, 2001. View at Publisher · View at Google Scholar · View at Scopus
  83. M. P. Link, A. M. Goorin, A. W. Miser et al., “The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity,” The New England Journal of Medicine, vol. 314, no. 25, pp. 1600–1606, 1986. View at Publisher · View at Google Scholar · View at Scopus
  84. K. Ando, K. Mori, N. Corradini, F. Redini, and D. Heymann, “Mifamurtide for the treatment of nonmetastatic osteosarcoma,” Expert Opinion on Pharmacotherapy, vol. 12, no. 2, pp. 285–292, 2011. View at Publisher · View at Google Scholar · View at Scopus
  85. P. M. Anderson, M. Tomaras, and K. McConnell, “Mifamurtide in osteosarcoma-a practical review,” Drugs of Today, vol. 46, no. 5, pp. 327–337, 2010. View at Publisher · View at Google Scholar · View at Scopus
  86. K. Geddes, J. G. Magalhães, and S. E. Girardin, “Unleashing the therapeutic potential of NOD-like receptors,” Nature Reviews Drug Discovery, vol. 8, no. 6, pp. 465–479, 2009. View at Publisher · View at Google Scholar · View at Scopus
  87. J. E. Frampton, P. M. Anderson, A. J. Chou et al., “Mifamurtide: a review of its use in the treatment of osteosarcoma,” Pediatric Drugs, vol. 12, no. 3, pp. 141–153, 2010. View at Publisher · View at Google Scholar · View at Scopus
  88. E. G. MacEwen, I. D. Kurzman, R. C. Rosenthal et al., “Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide,” Journal of the National Cancer Institute, vol. 81, no. 12, pp. 935–938, 1989. View at Publisher · View at Google Scholar · View at Scopus
  89. P. A. Meyers, C. L. Schwartz, M. D. Krailo et al., “Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival—a report from the children's oncology group,” Journal of Clinical Oncology, vol. 26, no. 4, pp. 633–638, 2008. View at Publisher · View at Google Scholar · View at Scopus
  90. M. Ayyoub, R. N. Taub, M. L. Keohan et al., “The frequent expression of cancer/testis antigens provides opportunities for immunotherapeutic targeting of sarcoma,” Cancer Immunity, vol. 4, no. 7, 2004. View at Google Scholar
  91. R. Takahashi, Y. Ishibashi, K. Hiraoka et al., “Phase II study of personalized peptide vaccination for refractory bone and soft tissue sarcoma patients,” Cancer Science, vol. 104, no. 10, pp. 1285–1294, 2013. View at Publisher · View at Google Scholar · View at Scopus
  92. S. E. Finkelstein, M. Fishman, A. P. Conley, D. Gabrilovich, S. Antonia, and A. Chiappori, “Cellular immunotherapy for soft tissue sarcomas,” Immunotherapy, vol. 4, no. 3, pp. 283–290, 2012. View at Publisher · View at Google Scholar · View at Scopus
  93. C. Harrison, “Vaccines: nanorings boost vaccine adjuvant effects,” Nature Reviews Drug Discovery, vol. 13, no. 7, pp. 496–496, 2014. View at Google Scholar
  94. M. Vergati, C. Intrivici, N.-Y. Huen, J. Schlom, and K. Y. Tsang, “Strategies for cancer vaccine development,” Journal of Biomedicine and Biotechnology, vol. 2010, Article ID 596432, 13 pages, 2010. View at Publisher · View at Google Scholar · View at Scopus
  95. F. J. Hsu, C. Benike, F. Fagnoni et al., “Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells,” Nature Medicine, vol. 2, no. 1, pp. 52–58, 1996. View at Publisher · View at Google Scholar · View at Scopus
  96. C. M. Celluzzi, J. I. Mayordomo, W. J. Storkus, M. T. Lotze, and L. D. Falo Jr., “Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity,” Journal of Experimental Medicine, vol. 183, no. 1, pp. 283–287, 1996. View at Publisher · View at Google Scholar · View at Scopus
  97. J. D. Geiger, R. J. Hutchinson, L. F. Hohenkirk et al., “Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression,” Cancer Research, vol. 61, no. 23, pp. 8513–8519, 2001. View at Google Scholar · View at Scopus
  98. H. L. Chen and D. P. Carbone, “p53 as a target for anti-cancer immunotherapy,” Molecular Medicine Today, vol. 3, no. 4, pp. 160–167, 1997. View at Publisher · View at Google Scholar · View at Scopus
  99. S. Gnjatic, H. Nishikawa, A. A. Jungbluth et al., “NY-ESO-1: review of an immunogenic tumor antigen,” Advances in Cancer Research, vol. 95, pp. 1–30, 2006. View at Publisher · View at Google Scholar · View at Scopus
  100. S. A. Rosenberg, “A new era for cancer immunotherapy based on the genes that encode cancer antigens,” Immunity, vol. 10, no. 3, pp. 281–287, 1999. View at Publisher · View at Google Scholar · View at Scopus
  101. A. Kawai, J. Woodruff, J. H. Healey, M. F. Brennan, C. R. Antonescu, and M. Ladanyi, “SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma,” The New England Journal of Medicine, vol. 338, no. 3, pp. 153–160, 1998. View at Publisher · View at Google Scholar · View at Scopus
  102. S. Kawaguchi, T. Wada, K. Ida et al., “Phase I vaccination trial of SYT-SSX junction peptide in patients with disseminated synovial sarcoma,” Journal of Translational Medicine, vol. 3, article 1, 2005. View at Publisher · View at Google Scholar · View at Scopus
  103. L. He, H. Feng, A. Raymond et al., “Dendritic-cell-peptide immunization provides immunoprotection against bcr-abl-positive leukemia in mice,” Cancer Immunology, Immunotherapy, vol. 50, no. 1, pp. 31–40, 2001. View at Publisher · View at Google Scholar · View at Scopus
  104. R. Yamanaka, N. Yajima, T. Abe et al., “Dendritic cell-based glioma immunotherapy (review),” International Journal of Oncology, vol. 23, no. 1, pp. 5–15, 2003. View at Google Scholar · View at Scopus
  105. A. J. G. Simpson, O. L. Caballero, A. Jungbluth, Y.-T. Chen, and L. J. Old, “Cancer/testis antigens, gametogenesis and cancer,” Nature Reviews Cancer, vol. 5, no. 8, pp. 615–625, 2005. View at Publisher · View at Google Scholar · View at Scopus
  106. R. L. Jones, S. M. Pollack, E. T. Loggers, E. T. Rodler, and C. Yee, “Immune-based therapies for sarcoma,” Sarcoma, vol. 2011, Article ID 438940, 7 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  107. C. Roeder, B. Schuler-Thurner, S. Berchtold et al., “MAGE-A3 is a frequent tumor antigen of metastasized melanoma,” Archives of Dermatological Research, vol. 296, no. 7, pp. 314–319, 2005. View at Publisher · View at Google Scholar · View at Scopus
  108. W. Sienel, C. Varwerk, A. Linder et al., “Melanoma associated antigen (MAGE)-A3 expression in Stages I and II non-small cell lung cancer: results of a multi-center study,” European Journal of Cardio-Thoracic Surgery, vol. 25, no. 1, pp. 131–134, 2004. View at Publisher · View at Google Scholar · View at Scopus
  109. O. L. Caballero and Y.-T. Chen, “Cancer/testis (CT) antigens: potential targets for immunotherapy,” Cancer Science, vol. 100, no. 11, pp. 2014–2021, 2009. View at Publisher · View at Google Scholar · View at Scopus
  110. M. E. Dudley and S. A. Rosenberg, “Adoptive-cell-transfer therapy for the treatment of patients with cancer,” Nature Reviews Cancer, vol. 3, no. 9, pp. 666–675, 2003. View at Publisher · View at Google Scholar · View at Scopus
  111. D. W. Lee, D. M. Barrett, C. Mackall, R. Orentas, and S. A. Grupp, “The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer,” Clinical Cancer Research, vol. 18, no. 10, pp. 2780–2790, 2012. View at Publisher · View at Google Scholar · View at Scopus
  112. J. Weber, “Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events,” The Oncologist, vol. 12, no. 7, pp. 864–872, 2007. View at Publisher · View at Google Scholar · View at Scopus
  113. F. S. Hodi, S. J. O'Day, D. F. McDermott et al., “Improved survival with ipilimumab in patients with metastatic melanoma,” The New England Journal of Medicine, vol. 363, no. 8, pp. 711–723, 2010. View at Publisher · View at Google Scholar · View at Scopus
  114. K. Wiater, T. Witaj, J. Mackiewicz et al., “Efficacy and safety of ipilimumab therapy in patients with metastatic melanoma: a retrospective multicenter analysis,” Contemporary Oncology, vol. 17, no. 3, pp. 257–262, 2013. View at Publisher · View at Google Scholar · View at Scopus
  115. E. D. Deeks, “Nivolumab: a review of its use in patients with malignant melanoma,” Drugs, vol. 74, no. 11, pp. 1233–1239, 2014. View at Publisher · View at Google Scholar
  116. S. L. Topalian, F. S. Hodi, J. R. Brahmer et al., “Safety, activity, and immune correlates of anti-PD-1 antibody in cancer,” The New England Journal of Medicine, vol. 366, no. 26, pp. 2443–2454, 2012. View at Publisher · View at Google Scholar · View at Scopus
  117. J. D. Wolchok, H. Kluger, M. K. Callahan et al., “Nivolumab plus Ipilimumab in advanced melanoma,” The New England Journal of Medicine, vol. 369, no. 2, pp. 122–133, 2013. View at Publisher · View at Google Scholar · View at Scopus
  118. M. Farazuddinm, B. Sharma, A. A. Khan, B. Joshi, and M. Owais, “Anticancer effcacy of perillyl alcohol-bearing PLGA microparticles,” International Journal of Nanomedicine, vol. 7, pp. 35–47, 2012. View at Google Scholar · View at Scopus
  119. A. Khan, Y. Shukla, N. Kalra et al., “Potential of diallyl sulfide bearing pH-sensitive liposomes in chemoprevention against DMBA-induced skin papilloma,” Molecular Medicine, vol. 13, no. 7-8, pp. 443–451, 2007. View at Publisher · View at Google Scholar · View at Scopus
  120. M. Farazuddin, B. Dua, Q. Zia, A. A. Khan, B. Joshi, and M. Owais, “Chemotherapeutic potential of curcumin-bearing microcells against hepatocellular carcinoma in model animals,” International Journal of Nanomedicine, vol. 9, no. 1, pp. 1139–1152, 2014. View at Publisher · View at Google Scholar
  121. A. Chauhan, S. Zubair, A. Nadeem, S. A. Ansari, M. Y. Ansari, and O. Mohammad, “Escheriosome-mediated cytosolic delivery of PLK1-specific siRNA: potential in treatment of liver cancer in BALB/c mice,” Nanomedicine, vol. 9, no. 4, pp. 407–420, 2014. View at Publisher · View at Google Scholar · View at Scopus
  122. A. Chauhan, S. Zubair, S. Tufail et al., “Fungus-mediated biological synthesis of gold nanoparticles: potential in detection of liver cancer,” International Journal of Nanomedicine, vol. 6, pp. 2305–2319, 2011. View at Google Scholar · View at Scopus
  123. H. Singha, A. I. Mallick, C. Jana, N. Fatima, M. Owais, and P. Chaudhuri, “Co-immunization with interlukin-18 enhances the protective efficacy of liposomes encapsulated recombinant Cu-Zn superoxide dismutase protein against Brucella abortus,” Vaccine, vol. 29, no. 29-30, pp. 4720–4727, 2011. View at Publisher · View at Google Scholar · View at Scopus
  124. M. A. Khan, A. Aljarbou, A. Khan, and M. Owais, “Immune stimulating and therapeutic potential of tuftsin-incorporated nystatin liposomes against Cryptococcus neoformans in leukopenic BALB/C mice,” FEMS Immunology and Medical Microbiology, vol. 66, no. 1, pp. 88–97, 2012. View at Publisher · View at Google Scholar · View at Scopus
  125. M. A. Khan, A. Khan, and M. Owais, “Prophylactic use of liposomized tuftsin enhances the susceptibility of Candida albicans to fluconazole in leukopenic mice,” FEMS Immunology and Medical Microbiology, vol. 46, no. 1, pp. 63–69, 2006. View at Publisher · View at Google Scholar · View at Scopus
  126. M. A. Khan and M. Owais, “Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model,” Journal of Antimicrobial Chemotherapy, vol. 58, no. 1, pp. 125–132, 2006. View at Publisher · View at Google Scholar · View at Scopus
  127. M. A. Khan, S. M. Faisal, and O. Mohammad, “Safety, efficacy and pharmacokinetics of tuftsin-loaded nystatin liposomes in murine model,” Journal of Drug Targeting, vol. 14, no. 4, pp. 233–241, 2006. View at Publisher · View at Google Scholar · View at Scopus
  128. A. Khan, A. A. Khan, V. Dwivedi, M. G. Ahmad, S. Hakeem, and M. Owais, “Tuftsin augments antitumor efficacy of liposomized etoposide against fibrosarcoma in Swiss albino mice,” Molecular Medicine, vol. 13, no. 5-6, pp. 266–276, 2007. View at Publisher · View at Google Scholar · View at Scopus
  129. J. Crespo, H. Sun, T. H. Welling, Z. Tian, and W. Zou, “T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment,” Current Opinion in Immunology, vol. 25, no. 2, pp. 214–221, 2013. View at Publisher · View at Google Scholar · View at Scopus